Chronic inflammatory demyelinating polyradiculoneuropathy

This study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 218 adults who have used IVIg before will receive either t…

This phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …

This study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…

This Phase 2b study tests whether the drug IMVT-1402 can help adults with CIDP, a nerve disorder causing weakness and numbness. About 162 participants will receive either the drug or a placebo weekly for up to 52 weeks. The main goal is to see if the drug keeps the disease from w…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C…

This Phase 3 trial tests whether the drug claseprubart (DNTH103) can prevent relapses in adults with CIDP, a nerve disorder that causes weakness and disability. About 256 participants will receive either the drug or a placebo. The main goal is to see how long it takes for symptom…

This study tests whether the drug nipocalimab can delay or prevent relapses in adults with CIDP, a rare nerve disorder that causes weakness and numbness. Participants first receive nipocalimab, and those who improve are then randomly assigned to continue the drug or switch to a p…

This study tests a new drug called riliprubart against standard IVIg treatment in 160 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants currently on IVIg will be randomly assigned to receive either r…

This early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…

This phase 3 trial tests two different doses of Panzyga, an intravenous immunoglobulin therapy, in children aged 2 to 17 with CIDP, a rare nerve condition causing weakness and disability. The study aims to see which dose better controls symptoms and prevents relapses, using a dis…

This study looks at two different doses of a medicine called Privigen in children aged 2 to 17 with a nerve disease called CIDP. The goal is to see which dose better prevents the disease from getting worse. About 30 children will take part, and the study is currently recruiting.

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…

This early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…

This study compares two treatments for CIDP, a nerve condition that causes weakness and numbness. It involves 20 adults who did not get better with steroids. One group receives a blood-filtering procedure called immunoadsorption, and the other receives standard antibody infusions…

This Phase 2 study is testing TAK-411, a specially modified immune globulin, in 36 adults with CIDP, an autoimmune disease that attacks nerve insulation and causes muscle weakness. The main goal is to see if TAK-411 improves physical function over 24 weeks compared to historical …

This study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over up to 2 years in everyday clinical settings. The…

This program offers efgartigimod PH20 SC to adults with CIDP who cannot join clinical trials and have not been helped by existing treatments. The drug is injected under the skin and aims to control the disease. The program continues until the patient stops treatment or the drug b…

This early-stage study tests a new cell therapy called CNCT19 in 18 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The goal is to see if it is safe and can help control the disease by targeting certain immune cells. Partici…

This phase 3 trial is testing whether a new, more concentrated antibody treatment (TAK-881) works similarly to the current standard (HYQVIA) for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). About 59 participants who already receive antibody infusi…

This early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with severe autoimmune diseases like multiple sclerosis, myasthenia gravis, and neuromyelitis op…

This study follows 30 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will use questionnaires and medical records to understand why patients chose to switch, how satisfied they are, and how the treatment …

This study is testing a blood-filtering treatment called immunoadsorption for people with CIDP, a nerve disorder causing weakness and numbness. About 140 adults who did not get better with standard treatments will be observed for 18 months. The goal is to see if immunoadsorption …

This study tests whether balance rehabilitation that changes how patients see (closing eyes, using a mask, or projecting moving dots) can improve walking stability better than standard rehab with eyes open. It includes 40 adults with chronic nerve damage who have trouble with bal…

This study tests whether whole-body electrical muscle stimulation (WB-EMS) can help adults with neuromuscular diseases like ALS, SMA, and muscular dystrophy exercise safely. Because these conditions weaken the nerves that control muscles, traditional exercise is often too hard. W…

This study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…

This observational study follows about 200 people in the United States who have chronic inflammatory demyelinating polyneuropathy (CIDP) and still experience disability despite at least three months of standard treatment. Researchers will track changes in disability scores and ex…

This study looks at whether smartwatches can help monitor chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disease that causes weakness and numbness. 35 adults with CIDP who use subcutaneous immunoglobulin therapy at home will wear a smartwatch for 12 months…

This study looks at how nerves work in people with Charcot-Marie-Tooth disease and other nerve disorders like CIDP. Researchers will use special electrical tests and ultrasound to measure nerve and muscle changes. The goal is to better understand these conditions, not to test a n…

This study follows pregnant women who have taken efgartigimod for myasthenia gravis or CIDP, as well as women exposed only during breastfeeding. Researchers will monitor pregnancy outcomes and infant health, including birth defects, to better understand the drug's safety. The goa…

This study looks at how a person's body composition (fat and muscle) affects the way immunoglobulin G (IgG) moves through the body after being given through a vein or under the skin. Researchers will enroll 20 adults with a nerve condition called CIDP who already receive IgG ther…

This study looks at whether ultrasound can detect nerve changes in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) earlier than standard tests. Researchers will compare ultrasound images with nerve conduction studies …